|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Addition of statins to the standard treatment in patients with cirrhosis:Safety and efficacy显示文摘This review summarizes the safety and efficacy of statins in patients with cirrhosis.Due to concerns about the safety of statins in patients with impaired liver function,they have recently been investigated as a potential treatment option in cirrhosis.The most clinically significant adverse event is statin-related myopathy,and this may be related to the high serum statin concentrations in the setting of severely impaired liver function.Rhabdomyolysis is the most serious and potentially life-threatening manifestation.It has recently been demonstrated that the recommended dose of simvastatin in patients with decompensated cirrhosis would be 20 mg/d because higher values,such as 40 mg/d,are associated with many adverse events,especially muscle injury.Likewise,simvastatin should not be administered to patients with Model for End-stage Liver Disease score>12 and/or Child-Pugh class C because of the high risk of severe muscle injury.Due to the pleiotropic effects,the focus on statins has shifted from being considered harmful to something useful.Through these effects,statins could prevent liver-related morbidity and mortality in cirrhotic patients.Observational studies in large populations of patients with cirrhosis have shown that treatment with statins to decrease high cholesterol levels was associated with a reduced risk of hepatic decompensation,hepatocellular carcinoma development and death.The few randomized controlled trials in patients with cirrhosis and portal hypertension showed that statins lower portal pressure,quite likely through a reduction in hepatic resistance.Another large randomized controlled trial in patients with variceal bleeding showed that simvastatin in addition to standard of care did not prevent rebleeding but improved survival rate.Despite these encouraging outcomes,the quality of the evidence regarding the use of statins is low or very low due to the observational characteristics of most of the studies involved.Therefore,it is advisable to perform further randomized controlled trials on a large series of patients with hard clinical endpoints,using different statin types and varying doses.The objectives would be to prevent liver-related morbidity and mortality rather than treating cirrhosis complications to take additional information that makes it possible to add statins to the standard of care of these patients. | Alberto E Muñoz Florencia D Pollarsky Mónica Marino Mariano Cartier Horacio Vázquez Pablo Salgado Gustavo Romero | 2021 | World Journal of Gastroenterology2021，27，28： | 4 |
| 2 | Systematic review:the Trousseau syndrome revisited:should we screen extensively for cancer in patients with venous thromboembolism?显示文摘 | Cartier M Le Gai G Wells PS | 2008 | Ann Intern Med2008，149，： | 1 |
| 3 | Nosiheptide,a sulfur-containing peptide antibiotic isolated from Strep40037显示文摘 | BANAZET F CARTIER M FLORENT J | 1980 | Experientia1980，36，： | 1 |
| 4 | Age-related differences in inflammatory markers in men:contribution of visceral adiposity显示文摘 | Cartier A Cote M | 2009 | Metabolism2009，58，10： | 1 |
| 5 | Age-related differences in inflammatory markers in men: contribution of visceral adiposity显示文摘 | Cartier A CSt 6 M Lemieux I | 2009 | Metabolism2009，58，10： | 1 |
| 6 | Quercintrin 3'-sulphate from leaves of Leea guinensis显示文摘 | Beck P D D B Dijoux M G Cartier G | 1998 | Phytochemistry1998，47，6： | 1 |
| 7 | The Us3 protein kinase of herpes simplex virus 1 blocks apoptosis and induces phosporylation of the Bc1-2 family member Bad显示文摘 | Cartier A Komai T Masucci M G | | 0，，01： | 1 |
| 8 | Defective human T - cell lympho- tropic virus type I (HTLV -I) provirus in 10 Chilean seronegative pa- tients with tropical spastic paraphrases or HTLV - I - associated myelop- athy 显示文摘 | Ramirez E Cartier L Rios M | 1998 | American Society for Microbiology1998，36，6： | 1 |
| 9 | Changing pattern in beating heart operations:use of skeletonized internal thoracic artery显示文摘 | Leacche M Couture P | 2002 | Ann Thorac Surg2002，74，5： | 1 |
| 10 | The information have-less: inequality, mobility, translocal networks in Chinese cit- ies显示文摘 | Cartier C Castells M Qiu J L | 2005 | Studies in Comparative International Development2005，40，1： | 1 |
| 11 | Ultrasound of thefetal thymus显示文摘 | Felker R Cartier M Emerson D Brown D | 1989 | J Ultrasound Med1989，8，12： | 1 |
| 12 | Risk factors of acute kid- hey injury according to RIFLE criteria after lung cancer surgery显示文摘 | Licker M Cartier V Robert J | 2011 | Ann Thorac Surg2011，91，： | 1 |
| 13 | Idiopathic inter-stitial pneumonias:diagnostic accuracy of thin-section CTin 129 patients显示文摘 | Johkoh T Müller NL Cartier Y | 1999 | Radiology1999，211，2： | 1 |
| 14 | Surgical management of valvular heart disease显示文摘 | Jamieson WR Cartier CP Allard M | 2004 | Can Cardiol2004，20，1： | 1 |
| 15 | Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function显示文摘 | Jeanmart H Malo O Cartier M | 2002 | J Heart Lung Transplant2002，21，9： | 1 |
| 16 | A key role for the mi-croglial NADPH oxidase in APP-dependent killing of neurons显示文摘 | Qin B Cartier L Dubois-Dauphin M | 2006 | Neurobiol Aging2006，27，11： | 1 |
| 17 | 显示文摘 | Gusev E P Copel M Cartier E | 2000 | Appl Phys Lett2000，76，： | 1 |
| 18 | Age-related differences in inflammatory markers in men:contribution of visceral adiposity显示文摘 | Cartier A Cote M | 2009 | Metabolism2009，58，10： | 1 |
| 19 | Ef- fective electron mobility in Si inversion layers in metal-oxide semiconductor systems with a high-k insulator: the role o{ re mote phonon scattering 显示文摘 | FISCHETTI M V NEUMAYER D A CARTIER E A | 2001 | Journal of Applied Physics2001，90，9： | 1 |
| 20 | High-resolution depth profiling in ultrathin Al2 O3 films on Si 显示文摘 | Gusev E P Copel M Cartier E | 2000 | Appl Phys Lett2000，76，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员